featured
Intensity-Modulated Radiotherapy vs Stereotactic Body Radiotherapy for Prostate Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Intensity-modulated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): 2-year toxicity results from an open-label, randomised, phase 3, non-inferiority trial
Lancet Oncol 2022 Sep 13;[EPub Ahead of Print], AC Tree, P Ostler, H van der Voet, W Chu, A Loblaw, D Ford, S Tolan, S Jain, A Martin, J Staffurth, J Armstrong, P Camilleri, K Kancherla, J Frew, A Chan, IS Dayes, A Duffton, DH Brand, D Henderson, K Morrison, S Brown, J Pugh, S Burnett, M Mahmud, V Hinder, O Naismith, E Hall, N van AsFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Advanced Prostate Cancer Center of Excellence
Visit our Advanced Prostate Cancer Center of Excellence for additional, in-depth coverage.